Los Angeles Capital Management LLC Reduces Stock Holdings in Edwards Lifesciences Corporation $EW

Los Angeles Capital Management LLC cut its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 76.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,726 shares of the medical research company’s stock after selling 42,334 shares during the period. Los Angeles Capital Management LLC’s holdings in Edwards Lifesciences were worth $995,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Econ Financial Services Corp purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $889,000. Pacific Capital Partners Ltd purchased a new position in Edwards Lifesciences during the second quarter worth $1,760,000. Arkadios Wealth Advisors acquired a new position in shares of Edwards Lifesciences in the second quarter worth $300,000. Mirova US LLC lifted its position in shares of Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares in the last quarter. Finally, Czech National Bank boosted its stake in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 22,970 shares of company stock worth $1,862,878 over the last ninety days. 0.34% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

EW stock opened at $85.55 on Thursday. The company has a market cap of $49.65 billion, a PE ratio of 12.31, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $77.99 and a two-hundred day moving average price of $77.59. Edwards Lifesciences Corporation has a 12-month low of $65.31 and a 12-month high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company posted $0.67 EPS. The company’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on EW. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Barclays reissued an “overweight” rating and issued a $99.00 price objective (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research note on Monday, November 3rd. Finally, National Bankshares set a $92.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.39.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.